69 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27287367	36	Evaluation of bisbenzamidines as inhibitors for matriptase-2.	University of Bonn
27015008	51	Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.	Bristol-Myers Squibb Research & Development
26985294	114	Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.	Southern Research
27073051	71	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.	Bristol-Myers Squibb
26732532	69	Active site-directed plasmin inhibitors: Extension on the P2 residue.	Kobe Gakuin University
26704266	80	Novel phenylalanine derived diamides as Factor XIa inhibitors.	Bristol-Myers Squibb
26421993	44	Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.	Aurigene Discovery Technologies
26367391	6	Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.	Heidelberg University
26393374	34	Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.	Queensland University of Technology
26114810	8	Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.	Southeast University
26122211	3	Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate.	Tokyo University of Pharmacy and Life Sciences
25592713	37	Pyridine and pyridinone-based factor XIa inhibitors.	Bristol-Myers Squibb
26151189	56	Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.	TBA
26005539	23	Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.	Bristol-Myers Squibb
25782055	9	Discovery of a Cyclic Boronic Acidß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.	Rempex Pharmaceuticals
25881820	62	Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.	Bristol-Myers Squibb R & D
25728130	79	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.	Bristol-Myers Squibb
24951330	25	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.	Bristol-Myers Squibb
25523211	18	Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.	Astellas Pharma
25438755	9	Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.	Astellas Pharma
25405503	109	Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.	Bristol-Myers Squibb
25179681	81	Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.	Chinese Academy of Sciences
12565961	177	Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.	Berlex Biosciences
11858993	60	Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds.	Corvas International
16759084	12	Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.	Peking University
15341970	59	P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
15203158	84	Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.	Merck
12482415	30	Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.	Merck Research Laboratories
11549459	5	Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase.	National Cancer Institute-Frederick
11425524	62	Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.	Axys Pharmaceuticals
32340773	110	Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.	Merck
32605372	92	A New Class of Dengue and West Nile Virus Protease Inhibitors with Submicromolar Activity in Reporter Gene DENV-2 Protease and Viral Replication Assays.	Heidelberg University
32150407	27	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.	Qpex Biopharma
11266160	57	Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.	Dupont Pharmaceuticals
11212109	14	The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase.	Roche Discover Welwyn
27434175	54	Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold.	The University of Queensland
27280436	304	Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines.	Philipps University Marburg
31679971	44	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.	University of Wollongong
31445854	43	Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.	Bristol-Myers Squibb
31395511	29	Structure-activity analysis of peptidic Chlamydia HtrA inhibitors.	University of Otago
30446438	36	Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.	China Pharmaceutical University
9873692	54	Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.	Dupont Pharmaceuticals
31833761	32	Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.	Bristol-Myers Squibb
9871573	15	Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.	Biotech Research Institute
30830783	13	Potential Anticancer Agents Characterized from Selected Tropical Plants.	The Ohio State University
31103899	15	Synthesis and structure-activity relationships of small-molecular di-basic esters, amides and carbamates as flaviviral protease inhibitors.	Heidelberg University
30613336	32	Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.	The University of Queensland
30833107	18	3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.	Universidade Federal Fluminense
31563807	63	Discovery of novel, potent, isosteviol-based antithrombotic agents.	Peking University
31413811	26	Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3.	The University of Queensland
24261937	6	Protease inhibitors from Microcystis aeruginosa bloom material collected from the Dalton Reservoir, Israel.	Tel-Aviv University
23777401	4	Aeruginosins from a Microcystis sp. bloom material collected in Varanasi, India.	Tel-Aviv University
23718637	1	Metabolites from Microcystis aeruginosa bloom material collected at a water reservoir near Kibbutz Hafetz Haim, Israel.	Tel-Aviv University
21506603	4	HCV-NS3/4A protease inhibitory iridoid glucosides and dimeric foliamenthoic acid derivatives from Anarrhinum orientale.	Cairo University
9214730	9	Effects of flavonoids isolated from scutellariae radix on fibrinolytic system induced by trypsin in human umbilical vein endothelial cells.	Ehime University
17350836	5	Synthesis of fluorescent-labeled aeruginosin derivatives for high-throughput fluorescence correlation spectroscopy assays.	Graduate School of Science and Engineering
29072911	16	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.	University of Nottingham
29550094	28	Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors.	Asubio Pharma
29501396	59	Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.	Bristol-Myers Squibb
30212625	107	Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.	German Cancer Research Center (Dkfz)
30130401	71	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.	University of Wollongong
29775297	7	Factor XIa Inhibitors as New Anticoagulants.	Bristol-Myers Squibb
29407959	82	The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.	Hefei University of Technology
29102227	19	Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors.	Asubio Pharma
29808677	5	Jizanpeptins, Cyanobacterial Protease Inhibitors from a Symploca sp. Cyanobacterium Collected in the Red Sea.	Oregon State University